RU2008142775A - Диагностика и лечение опухолей - Google Patents

Диагностика и лечение опухолей Download PDF

Info

Publication number
RU2008142775A
RU2008142775A RU2008142775/14A RU2008142775A RU2008142775A RU 2008142775 A RU2008142775 A RU 2008142775A RU 2008142775/14 A RU2008142775/14 A RU 2008142775/14A RU 2008142775 A RU2008142775 A RU 2008142775A RU 2008142775 A RU2008142775 A RU 2008142775A
Authority
RU
Russia
Prior art keywords
cells
subject
percentage
tumor
cell population
Prior art date
Application number
RU2008142775/14A
Other languages
English (en)
Russian (ru)
Inventor
Меган БОЛДУИН (US)
Меган БОЛДУИН
Наполеоне ФЕРРАРА (US)
Наполеоне ФЕРРАРА
Ханс-Петер ГЕРБЕР (US)
Ханс-Петер Гербер
Фарбод ШОДЖЕЙИ (US)
Фарбод ШОДЖЕЙИ
Цуйлин ЧЖУН (US)
Цуйлин ЧЖУН
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2008142775A publication Critical patent/RU2008142775A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2008142775/14A 2006-03-29 2007-03-28 Диагностика и лечение опухолей RU2008142775A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78772006P 2006-03-29 2006-03-29
US60/787,720 2006-03-29

Publications (1)

Publication Number Publication Date
RU2008142775A true RU2008142775A (ru) 2010-05-10

Family

ID=38564192

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008142775/14A RU2008142775A (ru) 2006-03-29 2007-03-28 Диагностика и лечение опухолей

Country Status (19)

Country Link
US (2) US20070264193A1 (enExample)
EP (1) EP1999151A2 (enExample)
JP (1) JP2009531463A (enExample)
KR (1) KR20080106946A (enExample)
CN (1) CN101448856A (enExample)
AR (1) AR060228A1 (enExample)
AU (1) AU2007233237A1 (enExample)
BR (1) BRPI0709425A2 (enExample)
CA (1) CA2647430A1 (enExample)
CL (1) CL2007000876A1 (enExample)
CR (1) CR10325A (enExample)
IL (1) IL193842A0 (enExample)
MA (1) MA30348B1 (enExample)
MX (1) MX2008012279A (enExample)
NO (1) NO20084546L (enExample)
RU (1) RU2008142775A (enExample)
TW (1) TW200806322A (enExample)
WO (1) WO2007115045A2 (enExample)
ZA (1) ZA200807590B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20110118185A9 (en) * 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
WO2009075768A2 (en) * 2007-12-07 2009-06-18 Children's Hospital Of Orange County Optical device and method for real-time chemosensitivity testing
EP2649995A3 (en) * 2008-02-29 2014-05-21 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth
WO2010017083A1 (en) * 2008-08-04 2010-02-11 Wayne State University Methods of treating cancer with cd11b antibodies
WO2010025414A2 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
US20110190380A1 (en) * 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
WO2010075420A1 (en) * 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
US7615353B1 (en) 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
AU2010278844A1 (en) * 2009-07-31 2012-02-09 Genentech, Inc. Inhibition of tumor metastasis using Bv8- or G-CSF-antagonists
KR20120059553A (ko) * 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
CA2790500A1 (en) * 2010-02-19 2011-08-25 Lynn K. Gordon Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
RU2014109985A (ru) * 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
RU2502471C9 (ru) * 2012-08-21 2015-04-20 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики
EP2741086A1 (en) * 2012-12-06 2014-06-11 Ludwig Boltzmann Gesellschaft Method for measuring coagulation of blood samples using viscoelastic tests (VET)
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
RU2546105C1 (ru) * 2014-04-29 2015-04-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет
WO2018078158A1 (en) * 2016-10-31 2018-05-03 Hexal Ag Antibody preparation
WO2020023183A1 (en) * 2018-07-24 2020-01-30 So Young Life Sciences Corporation Use of liposomes to deliver a protein and a gene encoding the protein to a live cell
US20200347449A1 (en) * 2019-05-01 2020-11-05 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
CN112946291A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4422551C1 (de) * 1994-06-28 1995-07-27 Daimler Benz Ag Durch Servomotor unterstützte Zahnstangenlenkung
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU4972900A (en) * 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ATE363291T1 (de) * 2000-06-23 2007-06-15 Bayer Schering Pharma Ag Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Also Published As

Publication number Publication date
MX2008012279A (es) 2008-10-08
KR20080106946A (ko) 2008-12-09
AU2007233237A1 (en) 2007-10-11
MA30348B1 (fr) 2009-04-01
JP2009531463A (ja) 2009-09-03
BRPI0709425A2 (pt) 2011-07-12
CL2007000876A1 (es) 2008-02-08
US20100239568A1 (en) 2010-09-23
ZA200807590B (en) 2009-11-25
TW200806322A (en) 2008-02-01
WO2007115045A3 (en) 2008-04-03
EP1999151A2 (en) 2008-12-10
CN101448856A (zh) 2009-06-03
WO2007115045A2 (en) 2007-10-11
US20070264193A1 (en) 2007-11-15
AR060228A1 (es) 2008-06-04
CA2647430A1 (en) 2007-10-11
IL193842A0 (en) 2011-08-01
NO20084546L (no) 2008-12-23
CR10325A (es) 2008-12-03

Similar Documents

Publication Publication Date Title
RU2008142775A (ru) Диагностика и лечение опухолей
Eulenberg et al. Hepatic fibrosis in dogs
JP2009531463A5 (enExample)
Eroğlu et al. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer
Wada et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation
Geng et al. Ultrasensitive optical detection and elimination of residual microtumors with a postoperative implantable hydrogel sensor for preventing cancer recurrence
WO2018050928A1 (en) Nox2 as a biomarker of radiotherapy efficiency in cancer patients
Ling et al. Serotonylation in tumor-associated fibroblasts contributes to the tumor-promoting roles of serotonin in colorectal cancer
Li et al. IL-6, TNF-α, and iNOS is associated with decreased colonic contraction in rats with multiple organ dysfunction syndrome
Lyubimova et al. Glial fibrillary acidic protein in the diagnosis and prognosis of malignant glial tumors
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
US10261085B2 (en) Treating bladder cancer patients and identifying bladder cancer patients responsive to treatment
Robak et al. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus
Liu et al. A preliminary study on the expression and clinical value of platelet-derived growth factor BB, hypoxia inducible factor-1α and CC motif chemokine receptor-2 in peripheral blood during the pathogenesis of Graves’ disease
Roberts et al. Ovarian dysgerminoma in an adolescent: A case report
Park et al. Correlation between SCC antigen and the prognosis of cervical cancer patients following concurrent chemoradiotherapy
Al Araji et al. Intrinsic Analysis of IL-17 and IL-10 Levels in the Serum of Non-Small Carcinoma Lung Cancer Patients at Stage IV compared to other Stages in Kerbala province/Iraq
Pauli et al. A POSSIBLE PROTECTIVE EFFECT OF THE PLASMA PCSK9 AGAINST MYOCARDIAL HYPERTROPHY AND DIASTOLIC DYSFUNCTION.
RU2821748C2 (ru) Способы диагностики инсульта, эффективности терапии, определения риска инсульта
H Naqvi et al. Serum Hepcidin: Its Correlation with Serum Ferritin, Serum Iron and Hemoglobin in Patients of Iron Deficiency Anemia
CN111254195B (zh) 一种用于预测大肠癌化疗效果的生物标志物、试剂盒及其应用
Fina et al. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1
Lepara et al. Elevated serum CRP level as potential biomarker of different stages of bladder cancer
RU2290640C1 (ru) Способ прогнозирования продолжительности жизни больных серозной карциномой яичников детородного возраста
Chen* MP17-17 MULTI-OMICS PERSPECTIVE ON THE TUMOR MICROENVIRONMENT BASED ON PD-L1 AND CD8 T-CELL INFILTRATION IN UROTHELIAL CANCER

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120312